Resonance Health Ltd · ASX:RHT
Resonance Health — Investor Presentation (November 2022)
16 slides from Resonance Health's investor presentation, Nov 24, 2022
Slide 1: Expanded capabilities, improved commercial outcomes
“Expanded capabilities, 22 improved commercial 20 outcomes” INVESTOR PRESENTATION 24 November 2022
Slide 2: Disclaimer
DISCLAIMER This presentation has been prepared by Resonance Health Ltd (“Resonance Health” or “Company”) and may contain forward-looking statements that are based on current expectations and beliefs and are subject to numerous factors and uncertainties that could cause actual results to differ mater
Slide 3: Corporate Information
CORPORATE INFORMATION Resonance Health provides medical devices and services for non- Shareholder Information invasive assessment of organ health. We accurately assess organ- iron and organ-fat, and other organ-biomarkers. Our services are ASX Code: RHT used by clinicians and patients globally, faci
Slide 4: The Why – Endemic Liver Disease
THE WHY – ENDEMIC LIVER DISEASE LIVER DISEASES GROWTH IN LIVER DISEASE MORTALITY Liver Disease mortality Fatty Liver Disease Iron Overload Diseases vastly outstripping Associated with obesity, 250M haemoglobin disease other diseases diabetes, hypertension. gene carriers 400K carrying The Lancet, Vol
Slide 5: The How – Liver Assessment
THE HOW – LIVER ASSESSMENT RESONANCE HEALTH CENTRAL (DRY-LAB) SERVICES* CLINICAL TRIAL SERVICES CENTRAL (WET-LAB) SERVICES* IMAGING MEDICAL DEVICES CRO TRIAL MANAGMENT BIOMEDICAL ANALYSIS • 6 regulatory cleared medical devices • Decades of experience in clinical trials • New wet-lab established in P
Slide 6: Imaging Analysis (Dry-Lab) Services
IMAGING ANALYSIS (DRY-LAB) SERVICES CORE LAB SERVICE ARTIFICIAL INTELLIGENCE “Resonance Health’s medical imaging analysis services and • Analyses liver-iron-concentration • Analyses cardiac (heart) iron • Most widely used method for this • Analyses liver-iron-concentration software-medical-devices a
Slide 7: Imaging Analysis (Dry-Lab) Services
IMAGING ANALYSIS (DRY-LAB) SERVICES RESEARCH SERVICES MRI CALIBRATION DEVICES • Analyses organ-iron using MRI • Analyses organ-fat using MRI • T1MES phantom for T1+ECV map • T2MES phantom for T2+ECV map • Including brain, kidney, pancreas • Including pancreas and spleen • Used to correctly calibrate
Slide 8: Clinical Trial Management + CRO Services
CLINICAL TRIAL MANAGEMENT + CRO SERVICES TRIAL CRO DRY-LAB WET-LAB “Resonance Clinical is a new commercial initiative aimed at the lucrative and expanding global clinical trial marketplace, especially for the treatment of liver diseases such as NAFLD, PHARMA IMAGING BIOMEDICINE which affects up to 3
Slide 9: Biomedical Central (Wet-Lab) Services
BIOMEDICAL CENTRAL (WET-LAB) SERVICES “In addition to standard biochemical + novel biomarker endpoints, our central wet-lab can offer disease associated panels for: • Liver Disease • Haematology • Metabolic, Obesity + Diabetes • Reproductive Endocrinology • Oncology CENTRAL WET-LAB • Neurology From
Slide 10: R&D + Innovation - Value Inflection Points
R&D + INNOVATION - VALUE INFLECTION POINTS Core Lab Services Innovation Proof of Concept IP Protection Clinical Validation Regulatory Commercialisation Shorter Acquisition Sequence (1.5 mins) 3T Scanner Calibration Shorter Acquisition Enhancement + Steatosis Enhancement + Steatosis AI Services Innov
Slide 11: R&D + Innovation - Value Inflection Points
R&D + INNOVATION - VALUE INFLECTION POINTS Proof of Concept Discovery + IP Protection Multi-Centre Clinical Validation Regulatory Clearances Commercialisation Completed “Resonance Health is working towards a non-invasive and standardized best-in-class assessment of liver fibrosis. Liver fibrosis ali
Slide 12: R&D + Innovation - Value Inflection Points
R&D + INNOVATION - VALUE INFLECTION POINTS The Company is developing novel blood markers with the potential to provide cost-effective assessments of iron-overload and liver-health for use in countries with limited access to MRI machines and/or when frequent cost-effective monitoring is warranted. Th
Slide 13: FY2022 Highlights
FY2022 HIGHLIGHTS Clinical Trials • Clinical trials valued at A$2.1M contracted including first service contract for HepaFat-AI • Entered China through first pharma service contract signed with a Chinese pharma • Post Period: contracted for two new clinical trials with combined value of A$1.5m Imagi
Slide 14: Expanded capabilities, improved commercial outcomes
“Ex pa n de dc ap ab ilit ies , im pro ve dc om me rc i al ou tc om es ” WWW.RESONANCEHEALTH.COM WWW.RESONANCECLINICAL.COM 141 Burswood + 61 892865300 info@resonancehealth.com Rd Burswood WA 6100 Australia
Slide 15: Appendix – Description of Dry + Wet Lab
APPENDIX – DESCRIPTION OF DRY + WET LAB Source: https://universitylabpartners.org/
Slide 16: Appendix - Global Prevalence of Diseases
APPENDIX - GLOBAL PREVALENCE OF DISEASES MAIN DISEASE FOCUS AREAS PREVALENCE OF IRON-OVERLOARD DISEASES PREVALENCE OF FATTY LIVER + CARDIOVASCULAR DISEASES *Source: World Distribution, Population Genetics and Health Burden of the Hemoglobinopathies. *Source: Nonalcoholic fatty liver disease and card
Resonance Health — Investor Presentation (November 2022) on 6ix